Pricing Log in Create free account
Saturday 7 November 2026 Export VERU’s income statement to Excel — free account

Veru Inc.

VERU Healthcare Biotechnology

Veru Inc.’s revenue for fiscal 2024 (year ended September 2024) was $16.9 million, up 3.62% from fiscal 2023.

EPS
+40.0%
Free cash flow
+0.27%

Quarter to June 2026, against a year earlier

2.14 0.08 +3.88%
Market cap
$35.1M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
5/9
Altman Z
−5.84
Beneish M
−3.38
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.00
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — 1 — — —
Sell — — — — — — — — — — — —
Insider Ownership 34.97%

Capital & Financial Ratios $m

Size
Market Cap 35.12
Revenue ttm 18.61
Net income ttm (13.61)
Free cash flow ttm (26.04)
Net debt Q (25.79)
Valuation
P/E 0.00
Forward P/E (1.38) (negative: loss-making)
Price / sales 2.65
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.74
Financial health
Current ratio Q 4.42 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (19.46)
Growth
Revenue growth Q +99.23% (above 0%: growing)
Operating income growth Q −2.22% (below 0%: shrinking)
EPS, this year +47.96% (at or above 15%: strong)
EPS, next year A −2.89% (below 0%: weak)
Revenue, next year A −94.82% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +33.14% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.4×, against a ten-year median of 4.4×; over the ten years it ranged from 0.6× in 2025 to 23.0× in 2022.
P/S against its own 10 years 18.15%
10-year low 10-year high
P/B against its own 10 years 25.37%
10-year low 10-year high
EV/Sales against its own 10 years 14.19%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 10 26 18 26
Receivables 5 4 — —
Inventory 7 4 — —
Other — — — —
23 35 19 27
2023 2024 2025 Q'26
Payables 13 2 3 2
ST’ Debt — — — —
Other 1 1 — —
18 12 8 6

Compound Annual Growth %

10y 5y 3y
Sales (3.65%) (11.89%) (34.92%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value (5.75%) (9.45%) (39.50%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.32 Actual −0.30

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.55 −0.50 Beat by 0.05
Q1 FY26 −0.47 −0.26 Beat by 0.21
Q2 FY26 −0.37 −0.13 Beat by 0.24
Q3 FY26 −0.32 −0.30 Beat by 0.02
Q4 FY26 −0.34 — Reports 16 December 2026

EPS $

Dec Mar Jun Sep Year
’26 (0.26) (0.12) (0.30) — —
’25 (0.60) (0.54) (0.50) 0.10 (1.55)
’24 (0.80) (0.70) (0.70) (0.60) (2.80)
’23 (4.60) (4.80) (1.42) (0.90) (11.00)
’22 (0.80) (1.80) (2.80) (5.10) (10.50)
’21 2.30 (0.40) (0.30) (0.50) 0.90
’20 (0.50) (0.10) (0.50) (1.70) (2.80)
Fiscal quarters ending in the months shown.

Revenue $m

Dec Mar Jun Sep Year
’26 — — — — —
’24 — 4 4 7 17
’23 3 7 3 4 16
’22 14 13 10 3 39
’21 15 13 18 16 61
’20 11 10 10 12 43
’19 6 7 10 9 32
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 (6) (9) (5) — —
’25 (11) (8) (5) (5) (30)
’24 (6) (6) (6) (4) (22)
’23 (35) (26) (18) (9) (88)
’22 (9) (4) (14) (21) (48)
’21 1 (3) (13) (1) (16)
’20 (3) (2) 3 0 (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 (6) (9) (5) — —
’25 (11) (8) (5) (5) (30)
’24 (6) (6) (6) (4) (22)
’23 (35) (26) (18) (10) (89)
’22 (9) (4) (14) (21) (48)
’21 1 (3) (13) (1) (16)
’20 (3) (2) 3 0 (2)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 22 14 16 32 43 61 39 16 17 — 19 (3.3%) 13 13 13 0.0%
Gross margin, % 60.33 51.40 55.30 68.10 72.28 78.24 77.73 46.43 34.67 — 43.39 (25.7) pt
EBT 3 (9) (23) (12) (20) 4 (84) (93) (35) (16) (14) n/m
EBT margin, % 12.72 (63.00) (145.43) (38.74) (47.08) 6.96 (212.95) (568.65) (208.81) 0.00 0.00 (12.7) pt
Net income 0 (7) (24) (12) (19) 7 (84) (93) (38) (23) (14) n/m
Per share, $
Per share, $ Revenue 7.72 3.94 2.95 5.02 6.38 8.03 4.91 1.92 1.25 0.00 0.00 n/m
Earnings 0.10 (2.50) (4.40) (1.90) (2.80) 1.00 (10.50) (11.00) (2.80) (1.55) (0.58) n/m
Cash flow (0.60) 0.28 (2.14) (0.87) (0.29) (2.04) (5.93) (10.36) (1.61) (2.05) (1.13) +14.7%
Capex 0.00 (0.04) (0.01) (0.02) (0.02) (0.05) (0.09) (0.08) (0.01) 0.00 0.00 (29.1%)
Free cash flow (0.60) 0.25 (2.15) (0.88) (0.30) (2.09) (6.02) (10.44) (1.62) (2.05) (1.13) +14.6%
Book value 11.84 13.99 5.47 5.11 4.51 19.97 10.33 2.32 2.40 1.25 1.23 (22.1%)
Shares, m 3 3 5 6 7 8 8 8 13 15 20 +19.9%
Valuation, ×
Valuation, × P/E 108.73 0.00 0.00 0.00 0.00 65.62 0.00 0.00 0.00 — 0.00 19.4
P/S 1.58 5.76 4.45 4.30 4.11 10.62 23.45 3.80 5.57 — 2.65 7.1
P/B 1.03 1.62 2.39 4.23 5.81 4.27 11.15 3.15 3.21 — 1.74 4.1
EV/Sales 1.47 5.52 4.80 4.36 3.98 8.68 21.50 3.41 4.37 — 1.44 6.5
EV/FCF (18.94) 88.72 (6.57) (24.79) (83.25) (33.33) (17.54) (0.63) (3.69) — (1.03) (11.1)
Cash, $m
Cash, $m Operating cash flow (2) 1 (12) (5) (2) (16) (48) (88) (22) (30) (26) +37.5%
Capex 0 0 0 0 0 0 (1) (1) 0 0 0 (17.8%)
Free cash flow (2) 1 (12) (6) (2) (16) (48) (89) (22) (30) (26) +37.4%
Balance, $m
Balance, $m Working capital 13 5 (2) 3 12 136 65 5 23 11 21 (1.7%)
Net debt (2) (3) 6 2 (8) (122) (80) (10) (26) (18) (26) +25.4%
Shareholders’ equity 34 48 29 32 30 152 83 20 32 18 28 (6.6%)
Returns, %
Returns, % ROA 0.91 (18.31) (46.13) (23.54) (36.08) 6.44 (53.61) (100.50) (68.45) (50.36) (42.29) (51.3) pt
ROIC 5.98 (11.75) (37.15) (11.72) (41.21) 27.09 (2,001.85) (583.07) (339.52) (120,852.54) (464.03) (120,858.5) pt
ROE 1.03 (20.88) (61.43) (38.88) (60.77) 8.11 (71.50) (181.80) (145.40) (89.74) (62.25) (90.8) pt
People
People Employees 156 175 171 386 339 252 233 189 210 20 — (20.4%)
Revenue/emp, $m 0.14 0.08 0.09 0.08 0.13 0.24 0.17 0.09 0.08 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Sep 2024 · latest quarter Sep 2024 · fundamentals updated 26 Oct 2026

Veru Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
GRCE Grace Therapeutics, Inc. $37.5M — (loss-making) — (loss-making) +5,127.27% (above 0%: growing) n/m −78.85% (below 0%: shrinking) 0.00% 0.00% Compare
ALDX Aldeyra Therapeutics, Inc. $37.2M — (loss-making) — — n/m +46.09% (above 0%: growing) 0.00% 0.00% Compare
TVGN Tevogen Inc. $36.2M — (loss-making) — — n/m +5.78% (above 0%: growing) — 0.00% Compare
PTHS Pelthos Therapeutics Inc. $35.6M — (loss-making) — (loss-making) — n/m −1,614.99% (below 0%: shrinking) 76.86% (111.02%) Compare
VERU Veru Inc. $35.1M — (loss-making) — (loss-making) +99.23% (above 0%: growing) n/m +0.27% (above 0%: growing) 67.84% 0.00%
LIANY LianBio Sponsored ADR $34.2M 0.0× — — n/m +1,107.59% (above 0%: growing) 0.00% 0.00% Compare
GRDX GridAI Technologies Corp. $33.3M — (loss-making) — — n/m −2,640.98% (below 0%: shrinking) (42.49%) (15,258.21%) Compare
NNVC NanoViricides, Inc. $32.9M — (loss-making) — — n/m −23.94% (below 0%: shrinking) 0.00% 0.00% Compare
PMN Promis Neurosciences $32.7M — (loss-making) — 0.00% n/m −169.46% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $34.9M — — — — −51.39% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 28 January 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.65m 1.38m 3.30
2024 1.98m 1.83m 6.68
2023 4.71m (5.95m) 6.25

Ownership

Directors and executive officers, together 14.20%
Alyeska Master Fund, L.P. 9.99%
Mitchell S. Steiner, M.D., F.A.C.S. 6.30%
Harry Fisch, M.D., F.A.C.S. 5.70%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Veru Inc. (VERU) Latest News

8 Sep

Impact 3 ·

17 Aug

Impact 4 · · The Motley Fool transcript

10 Aug

Impact 3 ·

4 Aug

Impact 3 ·

27 Jul

Impact 3 ·

5 Jun

Impact 4 · · Simply Wall St.

4 Jun

Impact 4 · · Stocktwits
Impact 4 · · InvestorsHub

1 Jun

Impact 4 · · Stocktwits transcript
Impact 3 · · Stocktwits transcript

29 May

Impact 3 · · Stocktwits transcript

15 May

Impact 3 · · Moby transcript

13 May

Impact 4 · · GuruFocus.com
Impact 4 · · Benzinga transcript
Impact 4 · · GlobeNewswire

9 Mar

Impact 4 · · GlobeNewswire

11 Feb

Impact 4 · · Moby transcript
Impact 4 · · GlobeNewswire
Impact 3 · · GuruFocus.comSimply Wall St.Insider MonkeyGuruFocus.comMT NewswiresZacksMotley FoolMT Newswires
Impact 3 · · The Motley Fool transcript

4 Feb

Impact 3 · · GlobeNewswire

17 Dec

Impact 4 · · GuruFocus.com
Impact 4 ·

4 Dec

Impact 3 · · GlobeNewswire

31 Oct

Impact 3 · · GlobeNewswire

30 Oct

Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · GlobeNewswire

8 Oct

Impact 4 ·

27 Sep

Impact 3 · · TipRanks

23 Sep

Impact 4 ·
stockrow.com/VERU · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com